TKNO on Nasdaq
Alpha Teknova, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with IMMUCELL CORP /DE/, TRINITY BIOTECH PLC or Intellia Therapeutics, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
33.2%Gross margin3
-41.9%Operating margin3
-42.6%Net margin3
7.4%Revenue growth, 20253
-25.1%Return on equity3
0.19×Debt to equity3
-$9.8MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Lab Essentials brought in 77% of the revenue Alpha Teknova, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Lab Essentials | $28.9M | $31.0M |
| Clinical Solutions | $7.1M | $7.7M |
| Other Product | $1.8M | $1.8M |
Regions
United States brought in 94% of the revenue Alpha Teknova, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $35.9M | $38.2M |
| Outside the United States | $1.8M | $2.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue67¢$27.1M
- Research and development5¢$2.2M
- Other costs28¢$11.2M
- Income tax0¢$58.0K
Out of $40.5M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $40.5M | $37.7M |
| Cost of sales | $27.1M | $30.5M |
| Gross profit | $13.4M | $7.2M |
| Research and development | $2.2M | $2.8M |
| Sales and marketing | $6.8M | $6.3M |
| General and administrative | $20.3M | $23.1M |
| Amortization of intangible assets | $1.1M | $1.1M |
| Total operating expenses | $30.4M | $33.4M |
| Loss from operations | -$17.0M | -$26.1M |
| Interest expense, net | -$710.0K | -$687.0K |
| Other adjustment to loan exit fee | $485.0K | $0 |
| Total other expenses, net | -$225.0K | -$687.0K |
| Loss before income taxes | -$17.2M | -$26.8M |
| Provision for (benefit from) income taxes | $58.0K | -$88.0K |
| Net loss | -$17.3M | -$26.7M |
| Net loss per share - basic | -$0.32 | -$0.57 |
| Net loss per share - diluted | -$0.32 | -$0.57 |
| Weighted average shares used in computing net loss per share - basic | 53.5M shares | 46.7M shares |
| Weighted average shares used in computing net loss per share - diluted | 53.5M shares | 46.7M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $5.9M | $3.7M | |
| Short-term investments, held -to-maturity | $15.4M | $26.7M | |
| Accounts receivable, net of allowance for credit losses of $23 thousand and $83 thousand as of December 31, 2025 and December 31, 2024, respectively | $4.6M | $4.3M | |
| Inventories, net | $7.1M | $6.8M | |
| Prepaid expenses and other current assets | $1.5M | $1.3M | |
| Total current assets | $34.5M | $42.8M | |
| Property, plant and equipment, net | $41.7M | $45.8M | |
| Operating right-of-use lease assets | $14.1M | $15.8M | |
| Intangible assets, net | $11.9M | $13.1M | |
| Other non-current assets | $1.3M | $1.4M | |
| Total assets | $103.6M | $118.8M | |
| Accounts payable | $1.4M | $825.0K | |
| Accrued liabilities | $4.3M | $4.5M | |
| Current portion of operating lease liabilities | $1.9M | $1.8M | |
| Current portion of long-term debt | $0 | $4.0M | |
| Total current liabilities | $7.5M | $11.2M | |
| Deferred tax liabilities | $879.0K | $827.0K | |
| Other accrued liabilities | $0 | $10.0K | |
| Long-term debt, net | $13.1M | $9.4M | |
| Long-term operating lease liabilities | $13.3M | $14.9M | |
| Total liabilities | $34.8M | $36.4M | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively, zero shares issued and outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.00001 par value, 490,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively, 53,562,154 and 53,409,727 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $1.0K | $1.0K | |
| Additional paid-in capital | $204.6M | $200.9M | |
| Accumulated deficit | -$135.8M | -$118.5M | |
| Total stockholders equity | $68.8M | $82.4M | $90.0M |
| Total liabilities and stockholders equity | $103.6M | $118.8M | |
| Allowance for doubtful accounts | $23.0K | $83.0K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 490.0M shares | 490.0M shares | |
| Common stock, shares issued | 53.6M shares | 53.4M shares | |
| Common stock, shares outstanding | 53.6M shares | 53.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$17.3M | -$26.7M |
| Bad debt expense | $68.0K | $130.0K |
| Inventory reserve | $2.1M | $4.5M |
| Depreciation and amortization | $6.3M | $6.6M |
| Stock-based compensation | $3.4M | $3.7M |
| Deferred taxes | $52.0K | -$92.0K |
| Accrued interest income on short-term investments | $29.0K | -$69.0K |
| Amortization of discount on short-term investments | -$614.0K | -$344.0K |
| Amortization of debt financing costs | $220.0K | $394.0K |
| Other adjustment to loan exit fee | -$485.0K | $0 |
| Non-cash lease expense | $117.0K | $182.0K |
| Loss on disposal of property, plant, and equipment | $19.0K | $233.0K |
| Accounts receivable | -$374.0K | -$494.0K |
| Inventories | -$2.4M | $244.0K |
| Prepaid expenses and other current assets | -$567.0K | -$18.0K |
| Other non-current assets | $97.0K | $470.0K |
| Accounts payable | $470.0K | -$594.0K |
| Accrued liabilities | $73.0K | -$389.0K |
| Other | -$10.0K | -$92.0K |
| Cash used in operating activities | -$8.6M | -$12.4M |
| Purchases of short-term investments | -$17.2M | -$30.3M |
| Maturities of short-term investments | $29.0M | $4.0M |
| Proceeds from sale of property, plant, and equipment | $0 | $125.0K |
| Purchase of property, plant and equipment | -$1.1M | -$1.1M |
| Cash provided by (used in) investing activities | $10.7M | -$27.3M |
| Proceeds from equity financing, net | $0 | $15.1M |
| Proceeds from long-term debt | $1.1M | $0 |
| Payment of exit fee costs | -$1.1M | $0 |
| Payment of debt issuance costs | -$100.0K | -$25.0K |
| Proceeds from financed insurance premiums | $333.0K | $385.0K |
| Repayment of financed insurance premiums | -$293.0K | -$738.0K |
| Proceeds from exercise of stock options | $100.0K | $29.0K |
| Proceeds from issuance of common stock under employee stock purchase plan | $111.0K | $135.0K |
| Cash provided by financing activities | $151.0K | $14.9M |
| Change in cash and cash equivalents | $2.2M | -$24.8M |
| Income taxes paid | $2.0K | $39.0K |
| Interest paid, net of amounts capitalized | $1.5M | $1.6M |
| Capitalized property, plant and equipment included in accounts payable and accrued liabilities | $149.0K | $104.0K |
| Recognition of operating right-of-use lease asset | $262.0K | $1.3M |
| Recognition of operating lease liabilities | $262.0K | $1.3M |
Recent filings
- Aug 6, 202610-Q
- Aug 5, 20268-K
- Jul 16, 20264 PRIMARY DOCUMENT
- Jun 2, 20264 PRIMARY DOCUMENT
- Jun 2, 20264 PRIMARY DOCUMENT
- Jun 2, 20264 PRIMARY DOCUMENT
- Jun 1, 20268-K
- May 7, 202610-Q
- May 6, 20268-K
- Apr 21, 2026DEF 14A
- Apr 21, 2026DEFA14A
- Apr 21, 2026ARS
- Mar 9, 20264 PRIMARY DOCUMENT
- Mar 9, 20264 PRIMARY DOCUMENT
- Mar 9, 20264 PRIMARY DOCUMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9